Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients

Introduction: The efficacy and tolerability of Enzalutamide and Abiraterone Acetate have been reported in elderly patients with metastatic castration resistant prostate cancer (mCRPC). However, there is no randomized study directly comparing antitumor effects between these 2 agents in geriatric...

書誌詳細
出版年:	Journal of Men's Health
主要な著者:	Ali Alkan, Zeynep Gülsüm Güç, Mustafa Gürbüz, Güliz Özgün, Serkan Değirmencioğlu, Mutlu Doğan, Tuğba Akın Telli, Özge Keskin, Çağatay Arslan, Burak Bilgin, Sema Sezgin Göksu, Hacer Demir, Elif Berna Köksoy, Osman Köstek, İsmail Ertürk, Teoman Şakalar, Arzu Yaşar, Görkem Türkkan, Büşra Kasım, Aziz Karaoğlu, Berna Çakmak Öksüzoğlu, Fulden Yumuk, Mehmet Ali Şendur, Hasan Şenol Coşkun, İrfan Çiçin, Nuri Karadurmuş, Özgür Tanrıverdi, Hakan Akbulut, Yüksel Ürün
フォーマット:	論文
言語:	英語
出版事項:	MRE Press 2021-09-01
主題:	metastatic castration-resistant prostate cancer enzalutamide abiraterone acetate elderly
オンライン･アクセス:	https://oss.jomh.org/jomh/article/20210928-455/pdf/JOMH2021011801.pdf

類似資料

Outcomes Management in a Real-World Evidence Context: The Case of Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer
著者:: Pedro Cardoso, 等
出版事項: (2020-05-01)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
著者:: Timothy C. Wright, 等
出版事項: (2021-07-01)

Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer
著者:: Stefanie Fischer, 等
出版事項: (2020-01-01)

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
著者:: Takashi Kawahara, 等
出版事項: (2023-03-01)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
著者:: Chi-Shin Tseng, 等
出版事項: (2023-06-01)

Mental health care utilization among men with castration‐resistant prostate cancer receiving abiraterone or enzalutamide
著者:: Phoebe A. Tsao, 等
出版事項: (2023-08-01)

Prognostic Nutritional Index and a Blood-Based Prognostic Tool in Prostate Cancer Treated with Abiraterone, Enzalutamide or Cabazitaxel
著者:: Hakan Taban, 等
出版事項: (2025-06-01)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
著者:: N. A. Avxentyev, 等
出版事項: (2019-01-01)

Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran
著者:: Zahra Goudarzi, 等
出版事項: (2024-02-01)

Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide
著者:: Onur Baser, 等
出版事項: (2024-04-01)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
著者:: Xiangyun You, 等
出版事項: (2023-04-01)

Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland
著者:: Dawid Sigorski, 等
出版事項: (2023-04-01)

THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER
著者:: A. A. GRITSKEVICH, 等
出版事項: (2017-06-01)

Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review
著者:: Wei Zhang, 等
出版事項: (2017-01-01)

Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate
著者:: Ondřej Fiala, 等
出版事項: (2024-01-01)

Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer
著者:: Marcus Moses, MS, 等
出版事項: (2020-01-01)

Short-term efficacy of enzalutamide in treatment of patients with abiraterone-resistant metastatic castration-resistant prostate cancer
著者:: MEI Jingchang, SU Xiaonan, YAO Yu, GUAN Fengju, ZHANG Guiming
出版事項: (2025-02-01)

Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
著者:: Armen Aprikian, 等
出版事項: (2025-02-01)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
著者:: N. K. Mazina, 等
出版事項: (2017-11-01)

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer
著者:: Takuya Tsujino, 等
出版事項: (2023-10-01)

Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives
著者:: Francesco Pinto, 等
出版事項: (2022-04-01)

Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec
著者:: Jason Hu, 等
出版事項: (2022-11-01)

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer
著者:: Khrystany T. Isebia, 等
出版事項: (2025-10-01)

Optimisation of second line antihormonal treatment for castration resistant metastatic prostate cancer
著者:: Kullmann Tamás, 等
出版事項: (2022-04-01)

Splice variants of androgen receptor and prostate cancer
著者:: Orazio Caffo, 等
出版事項: (2016-05-01)

Hormonal Intensification Should Start at the Low-risk Stage in Metastatic Prostate Cancer
著者:: Seyed Behzad Jazayeri, 等
出版事項: (2022-11-01)

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
著者:: Fatima Karzai, 等
出版事項: (2018-12-01)

Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology
著者:: Darren M. C. Poon, 等
出版事項: (2024-01-01)

Improving quality of life in metastatic castration-resistant prostate cancer: the role of androgen receptor axis-targeted agents
著者:: Monika Kuzma, 等
出版事項: (2023-07-01)

Sequential Androgen Receptor Pathway Inhibitor in Prostate Cancer: Piling-Up The Benefits or a Case for Cross-Resistance?
著者:: Bertrand Tombal
出版事項: (2014-11-01)

SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT
著者:: Sabin Göktaş Aydın, 等
出版事項: (2023-03-01)

Nonregional Lymph Node Metastasis as a Predictor of Early Progression When Using Androgen Receptor Targeting Agents in Patients With Metastatic Castration-Resistant Prostate Cancer Without Previous Chemotherapy
著者:: Sihyeon Kim, 等
出版事項: (2023-11-01)

Treatment sequencing in metastatic castrate-resistant prostate cancer
著者:: Oliver Sartor, 等
出版事項: (2014-06-01)

Current management of metastatic castration-sensitive prostate cancer
著者:: Adam Kessel, 等
出版事項: (2021-01-01)

Prolonged Response with Enzalutamide in a Prostate Cancer Patient on Hemodialysis
著者:: Ahmet Dirican, 等
出版事項: (2022-11-01)

Usage, effectiveness and safety of abiraterone in prostate cancer
著者:: J. M. Caro Teller, 等
出版事項: (2014-03-01)

Investigation into the Optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer
著者:: Yasuo Oguma, 等
出版事項: (2022-09-01)

Ailanthone: a new potential drug for castration-resistant prostate cancer
著者:: Shihong Peng, 等
出版事項: (2017-03-01)

Assessment of androgen receptor signaling inhibitors therapy in metastatic hormone-sensitive prostate cancer
著者:: Jukapun Yoodee, 等
出版事項: (2022-11-01)

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
著者:: Zhe Zhu, 等
出版事項: (2024-11-01)